CSA Medical, Inc., a Lutherville, Maryland-based provider of advanced spray cryotherapy technology, closed a $16m Series C financing.
The round was led by Ascension Ventures (AV) with participation from existing investors SV Life Sciences, Intersouth Partners, First Analysis, Blue Heron Capital, Rose Park and Guide Medical Ventures. In conjunction with the funding, Tara Butler, MD, Managing Director at AV, will join CSA Medical’s Board of Directors.
Led by Bill Floyd, CEO and President, CSA Medical develops and manufactures a proprietary interventional spray cryotherapy technology platform comprised of a device and specialty catheters that enable delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue.
The company intends to use the funds for the development of new applications and grow adoption of its truFreeze system, which is currently being used by physicians to ablate a variety of unwanted tissue inside the body such as in the esophagus and airway. The device delivers cold liquid nitrogen spray through a small catheter to enable physicians to flash-freeze targeted tissue.